Inventor
KLATZMANN DAVID
FR34 patents
⚠️ This page may combine multiple inventors who share the name “KLATZMANN DAVID”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV PARIS CURIE
10 patentsUS6365405B1Apr 2, 2002
Compositions of chondrocytes, preparation and utilization
UNIV PARIS CURIE184 citations95
US6872528B2Mar 29, 2005
Highly productive packaging lines
UNIV PARIS CURIE38 citations92
US6140114AOct 31, 2000
Defective viral vaccine particles obtained in vivo or ex vivo
UNIV PARIS CURIE52 citations92
US5948675ASep 7, 1999
Host-vector system which can be used in gene therapy
UNIV PARIS CURIE33 citations92
US5843432ADec 1, 1998
Retroviral vectors for the treatment of tumors, and cell lines containing them
UNIV PARIS CURIE9 citations69
US6333171B1Dec 25, 2001
CD4 gene regulatory sequences specifically expressed in mature T cells
UNIV PARIS CURIE4 citations58
US6004803ADec 21, 1999
Genes encoding HSV1-TK containing a deletion of 5' cryptic promoter sites, vectors and cell lines
UNIV PARIS CURIE6 citations54
US7504483B2Mar 17, 2009
α-β C4BP-type recombinant heteromultimeric proteins
UNIV PARIS CURIE0 citations52
US6383807B1May 7, 2002
Method of transforming T lymphocytes
UNIV PARIS CURIE0 citations52
US6048525AApr 11, 2000
Cells designed as traps and their use as medicines
UNIV PARIS CURIE1 citations52
INST NAT SANTE RECH MED
4 patentsUS10293028B2May 21, 2019
Use of low dose IL-2 for treating autoimmune related or inflammatory disorders
INST NAT SANTE RECH MED23 citations92
US10765723B2Sep 8, 2020
Use of low dose IL-2 for treating autoimmune—related or inflammatory disorders
INST NAT SANTE RECH MED5 citations82
US11559566B2Jan 24, 2023
Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders
INST NAT SANTE RECH MED1 citations71
US12491232B2Dec 9, 2025
Low dose IL-2 for treating autoimmune-related or inflammatory disorders
INST NAT SANTE RECH MED0 citations60
KLATZMANN DAVID
4 patentsUS9669071B2Jun 6, 2017
Method for stimulating T lymphocytes with IL-2
KLATZMANN DAVID13 citations89
US8673612B2Mar 18, 2014
Synthetic viruses and uses thereof
KLATZMANN DAVID18 citations88
US11648271B2May 16, 2023
Genetically modified T lymphocytes
KLATZMANN DAVID0 citations61
US9801927B2Oct 31, 2017
Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof
KLATZMANN DAVID0 citations44
UNIV SORBONNE
3 patentsUS10376564B2Aug 13, 2019
Interleukin-2 for treating food allergy
UNIV SORBONNE12 citations82
US11306294B2Apr 19, 2022
Virus-like particles which can be used in the treatment of autoimmune diseases
UNIV SORBONNE4 citations71
US12428625B2Sep 30, 2025
Virus-like particles which can be used in the treatment of allergies
UNIV SORBONNE0 citations60
ILTOO PHARMA
2 patentsCONSEJO NAC DE INVESTIG CIENTIFICAS Y TECN (CONICET)
2 patentsUS9757471B2Sep 12, 2017
Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
CONSEJO NAC DE INVESTIG CIENTIFICAS Y TECN (CONICET)0 citations45
US9457096B2Oct 4, 2016
Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
CONSEJO NAC DE INVESTIG CIENTIFICAS Y TECN (CONICET)0 citations45